Reliable Biomarkers and Predictors of Schizophrenia and its Treatment

Psychiatric Clinics of North America

Volumn 35, Issue 3, 2012, Pages 645-659

  Pillai, Anilkumar ^a   Buckley, Peter F ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Biomarker; Brain derived neurotrophic factor; Schizophrenia; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORPROMAZINE; CLOZAPINE; DNA METHYLTRANSFERASE 1; DOPA; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DYSBINDIN; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 67; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HALOPERIDOL; METHIONINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; OLANZAPINE; PARVALBUMIN; PHOSPHATIDYLINOSITOL 3 KINASE; POMAGLUMETAD METHIONIL; QUETIAPINE; REELIN; RISPERIDONE; VALINE;

4 AMINOBUTYRIC ACID RELEASE; AMINO ACID SUBSTITUTION; BRAIN DYSFUNCTION; COGNITION; DISEASE MARKER; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; ENDOPHENOTYPE; GABAERGIC TRANSMISSION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CARRIER PROTEINS; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; INDIVIDUALIZED MEDICINE; NERVE TISSUE PROTEINS; NEUREGULINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84865427931     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2012.06.006     Document Type: Review

References (106)

1. Higgins M.J., Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011, 121(10):3797-3803.
2. Maitland M.L., Schilsky R.L. Clinical trials in the era of personalized oncology. CA Cancer J Clin 2011, 61(6):365-381.
3. Holmes M.V., Perel P., Shah T., et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events. JAMA 2011, 306(24):2704-2714.
4. Snyderman R. Creating meaningful health care reform. J Clin Invest 2009, 119(10):2855-2856.
5. Barch D.M., Mathalon D.H. Using brain imaging measures in studies of precognitive pharmacologic agents in schizophrenia: psychometric and quality assurance considerations. Biol Psychiatry 2011, 70(1):13-18.
6. Carter C.S., Barch D.M., Bullmore E., et al. Cognitive neuroscience treatment research to improve cognition in schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry 2011, 70(1):7-12.
7. Luck S.J., Mathalon D.H., O'Donnell B.F., et al. A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol Psychiatry 2011, 70(1):28-34.
8. Cornblatt B.A., Malhotra A.K. Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am J Med Genet 2001, 105(1):11-15.
9. Moritz S., Heeren D., Andresen B., et al. An analysis of the specificity and the syndromal correlates of verbal memory impairments in schizophrenia. Psychiatry Res 2001, 101(1):23-31.
10. Glahn D.C., Kim J., Cohen M.S., et al. Maintenance and manipulation in spatial working memory: dissociations in the prefrontal cortex. Neuroimage 2002, 17(1):201-213.
11. Calkins M.E., Gur R.C., Ragland J.D., et al. Face recognition memory deficits and visual object memory performance in patients with schizophrenia and their relatives. Am J Psychiatry 2005, 162(10):1963-1966.
12. Conklin H.M., Curtis C.E., Calkins M.E., et al. Working memory functioning in schizophrenia patients and their first-degree relatives: cognitive functioning shedding light on etiology. Neuropsychologia 2005, 43(6):930-942.
13. Clementz B.A., McDowell J.E., Zisook S. Saccadic system functioning among schizophrenia patients and their first-degree biological relatives. J Abnorm Psychol 1994, 103(2):277-287.
14. Adler L.E., Freedman R., Ross R.G., et al. Elementary phenotypes in the neurobiological and genetic study of schizophrenia. Biol Psychiatry 1999, 46(1):8-18.
15. Levy D.L., Lajonchere C.M., Dorogusker B., et al. Quantitative characterization of eye tracking dysfunction in schizophrenia. Schizophr Res 2000, 42(3):171-185.
16. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001, 156(2-3):234-258.
17. Baldeweg T., Klugman A., Gruzelier J., et al. Mismatch negativity potentials and cognitive impairment in schizophrenia. Schizophr Res 2004, 69(2-3):203-217.
18. Bramon E., McDonald C., Croft R.J., et al. Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study. Neuroimage 2005, 27(4):960-968.
19. Davidson L.L., Heinrichs R.W. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res 2003, 122(2):69-87.
20. Davatzikos C., Shen D., Gur R.C., et al. Whole-brain morphometric study of schizophrenia revealing a spatially complex set of focal abnormalities. Arch Gen Psychiatry 2005, 62(11):1218-1227.
21. Thermenos H.W., Goldstein J.M., Buka S.L., et al. The effect of working memory performance on functional MRI in schizophrenia. Schizophr Res 2005, 74(2-3):179-194.
22. Greenwood T.A., Lazzeroni L.C., Murray S.S., et al. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry 2011, 168(9):930-946.
23. Laruelle M., Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999, 13(4):358-371.
24. Kim J.S., Kornhuber H.H., Schmid-Burgk W., et al. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980, 20(3):379-382.
25. Javitt D.C., Sershen H., Hashim A., et al. Inhibition of striatal dopamine release by glycine and glycyldodecylamide. Brain Res Bull 2000, 52(3):213-216.
26. Bartha R., Williamson P.C., Drost D.J., et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1997, 54(10):959-965.
27. Tuominen H.J., Tiihonen J., Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev 2006, (2). CD003730.
28. Patil S.T., Zhang L., Martenyi F., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007, 13(9):1102-1107.
29. Chaki S., Hikichi H. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia. Curr Pharm Des 2011, 17(2):94-102.
30. Gonzalez-Burgos G., Hashimoto T., Lewis D.A. Alterations of cortical GABA neurons and network oscillations in schizophrenia. Curr Psychiatry Rep 2010, 12(4):335-344.
31. Costa E., Chen Y., Dong E., et al. GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. Expert Rev Neurother 2009, 9(1):87-98.
32. Costa E., Chen Y., Davis J., et al. REELIN and schizophrenia: a disease at the interface of the genome and the epigenome. Mol Interv 2002, 2(1):47-57.
33. Schurov I.L., Handford E.J., Brandon N.J., et al. Expression of disrupted in schizophrenia 1 (DISC1) protein in the adult and developing mouse brain indicates its role in neurodevelopment. Mol Psychiatry 2004, 9(12):1100-1110.
34. Callicott J.H., Straub R.E., Pezawas L., et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci U S A 2005, 102(24):8627-8632.
35. Emamian E.S., Hall D., Birnbaum M.J., et al. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004, 36(2):131-137.
36. Freyberg Z., Ferrando S.J., Javitch J.A. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010, 167(4):388-396.
37. Xu M.Q., Xing Q.H., Zheng Y.L., et al. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry 2007, 68(9):1358-1367.
38. Thiselton D.L., Vladimirov V.I., Kuo P.H., et al. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry 2008, 63(5):449-457.
39. Benson M.A., Newey S.E., Martin-Rendon E., et al. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem 2001, 276(26):24232-24241.
40. Li W., Zhang Q., Oiso N., et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet 2003, 35(1):84-89.
41. Fanous A.H., van den Oord E.J., Riley B.P., et al. Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry 2005, 162(10):1824-1832.
42. Guo A.Y., Sun J., Riley B.P., et al. The dystrobrevin-binding protein 1 gene: features and networks. Mol Psychiatry 2009, 14(1):18-29.
43. Talbot K., Eidem W.L., Tinsley C.L., et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 2004, 113(9):1353-1363.
44. Tang J., LeGros R.P., Louneva N., et al. Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Hum Mol Genet 2009, 18(20):3851-3863.
45. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008, 9(6):437-452.
46. Stefansson H., Sigurdsson E., Steinthorsdottir V., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71(4):877-892.
47. Hong L.E., Wonodi I., Stine O.C., et al. Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biol Psychiatry 2008, 63(1):17-23.
48. McIntosh A.M., Moorhead T.W., Job D., et al. The effects of a neuregulin 1 variant on white matter density and integrity. Mol Psychiatry 2008, 13(11):1054-1059.
49. Winterer G., Konrad A., Vucurevic G., et al. Association of 5' end neuregulin-1 (NRG1) gene variation with subcortical medial frontal microstructure in humans. Neuroimage 2008, 40(2):712-718.
50. Lessmann V., Gottmann K., Malcangio M. Neurotrophin secretion: current facts and future prospects. Prog Neurobiol 2003, 69(5):341-374. [Erratum in: Prog Neurobiol 2004;72(2):165-6].
51. Murer M.G., Yan Q., Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2001, 63(1):71-124.
52. Bramham C.R., Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 2005, 76(2):99-125.
53. Minichiello L., Korte M., Wolfer D., et al. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 1999, 24(2):401-414.
54. Xu B., Gottschalk W., Chow A., et al. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci 2000, 20(18):6888-6897.
55. Mizuno K., Carnahan J., Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994, 165(1):243-256.
56. Arenas E., Akerud P., Wong V., et al. Effects of BDNF and NT-4/5 on striatonigral neuropeptides or nigral GABA neurons in vivo. Eur J Neurosci 1996, 8(8):1707-1717.
57. Brünig I., Penschuck S., Berninger B., et al. BDNF reduces miniature inhibitory postsynaptic currents by rapid downregulation of GABA(A) receptor surface expression. Eur J Neurosci 2001, 13(7):1320-1328.
58. Elmariah S.B., Crumling M.A., Parsons T.D., et al. Postsynaptic TrkB-mediated signaling modulates excitatory and inhibitory neurotransmitter receptor clustering at hippocampal synapses. J Neurosci 2004, 24(10):2380-2393.
59. Henneberger C., Kirischuk S., Grantyn R. Brain-derived neurotrophic factor modulates GABAergic synaptic transmission by enhancing presynaptic glutamic acid decarboxylase 65 levels, promoting asynchronous release and reducing the number of activated postsynaptic receptors. Neuroscience 2005, 135(3):749-763.
60. Yamada M.K., Nakanishi K., Ohba S., et al. Brain-derived neurotrophic factor promotes the maturation of GABAergic mechanisms in cultured hippocampal neurons. J Neurosci 2002, 22(17):7580-7585.
61. Vicario-Abejón C., Collin C., McKay R.D., et al. Neurotrophins induce formation of functional excitatory and inhibitory synapses between cultured hippocampal neurons. J Neurosci 1998, 18(18):7256-7271.
62. Linnarsson S., Björklund A., Ernfors P. Learning deficit in BDNF mutant mice. Eur J Neurosci 1997, 9(12):2581-2587.
63. Tyler W.J., Perrett S.P., Pozzo-Miller L.D. The role of neurotrophins in neurotransmitter release. Neuroscientist 2002, 8(6):524-531.
64. Figurov A., Pozzo-Miller L.D., Olafsson P., et al. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 1996, 381(6584):706-709.
65. Kang H., Welcher A.A., Shelton D., et al. Neurotrophins and time: different roles for TrkB signaling in hippocampal long-term potentiation. Neuron 1997, 19(3):653-664.
66. Ashe P.C., Chlan-Fourney J., Juorio A.V., et al. Brain-derived neurotrophic factor (BDNF) mRNA in rats with neonatal ibotenic acid lesions of the ventral hippocampus. Brain Res 2002, 956(1):126-135.
67. Fiore M., Korf J., Antonelli A., et al. Long-lasting effects of prenatal MAM treatment on water maze performance in rats: associations with altered brain development and neurotrophin levels. Neurotoxicol Teratol 2002, 24(2):179-191.
68. Angelucci F., Gruber S.H., El Khoury A., et al. Chronic amphetamine treatment reduces NGF and BDNF in the rat brain. Eur Neuropsychopharmacol 2007, 17(12):756-762.
69. Castrén E., da Penha Berzaghi M., Lindholm D., et al. Differential effects of MK-801 on brain-derived neurotrophic factor mRNA levels in different regions of the rat brain. Exp Neurol 1993, 122(2):244-252.
70. Angelucci F., Mathé A.A., Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000, 60(6):783-794.
71. Parikh V., Khan M.M., Mahadik S.P. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett 2004, 356(2):135-139.
72. Pillai A., Terry A.V., Mahadik S.P. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 2006, 82(1):95-106.
73. Lipska B.K., Khaing Z.Z., Weickert C.S., et al. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci 2001, 14(1):135-144.
74. Bai O., Chlan-Fourney J., Bowen R., et al. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003, 71(1):127-131.
75. Xu H., Qing H., Lu W., et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 2002, 321(1-2):65-68.
76. Thompson Ray M., Weickert C.S., Wyatt E., et al. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011, 36(3):195-203.
77. Weickert C.S., Hyde T.M., Lipska B.K., et al. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003, 8(6):592-610.
78. Hashimoto T., Bergen S.E., Nguyen Q.L., et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 2005, 25(2):372-383.
79. Dunham J.S., Deakin J.F., Miyajima F., et al. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J Psychiatr Res 2009, 43(14):1175-1184.
80. Pillai A. Decreased expression of Sprouty2 in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder: a correlation with BDNF expression. PLoS One 2008, 3(3):e1784.
81. Issa G., Wilson C., Terry A.V., et al. An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. Neurobiol Dis 2010, 39(3):327-333.
82. Carlino D., Leone E., Di Cola F., et al. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. J Psychiatr Res 2011, 45(2):273-279.
83. Buckley P.F., Pillai A., Evans D., et al. Brain derived neurotropic factor in first-episode psychosis. Schizophr Res 2007, 91(1-3):1-5.
84. Pillai A., Kale A., Joshi S., et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 2010, 13(4):535-539.
85. Jindal R.D., Pillai A.K., Mahadik S.P., et al. Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia. Schizophr Res 2010, 119(1-3):47-51.
86. Chen da C., Wang J., Wang B., et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 2009, 207(3):375-380.
87. Xiu M.H., Hui L., Dang Y.F., et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(8):1508-1512.
88. Reis H.J., Nicolato R., Barbosa I.G., et al. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neurosci Lett 2008, 439(2):157-159.
89. Takahashi M., Shirakawa O., Toyooka K., et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000, 5(3):293-300.
90. Soontornniyomkij B., Everall I.P., Chana G., et al. Tyrosine kinase B protein expression is reduced in the cerebellum of patients with bipolar disorder. J Affect Disord 2011, 133(3):646-654.
91. Hori H., Yoshimura R., Yamada Y., et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 2007, 22(1):21-27.
92. Yoshimura R., Hori H., Sugita A., et al. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(5):1072-1077.
93. Pang P.T., Teng H.K., Zaitsev E., et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004, 306(5695):487-491.
94. Chen Z.Y., Patel P.D., Sant G., et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004, 24(18):4401-4411.
95. Szeszko P.R., Lipsky R., Mentschel C., et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 2005, 10(7):631-636.
96. Agartz I., Sedvall G.C., Terenius L., et al. BDNF gene variants and brain morphology in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2006, 141B(5):513-523.
97. Chen Z.Y., Bath K., McEwen B., et al. Impact of genetic variant BDNF (Val66Met) on brain structure and function. Novartis Found Symp 2008, 289:180-188. [discussion: 188-95].
98. Dutt A., McDonald C., Dempster E., et al. The effect of COMT, BDNF, 5-HTT, NRG1 and DTNBP1 genes on hippocampal and lateral ventricular volume in psychosis. Psychol Med 2009, 39(11):1783-1797.
99. Koolschijn P.C., van Haren N.E., Bakker S.C., et al. Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia. Hippocampus 2010, 20(9):1010-1017.
100. Smith G.N., Thornton A.E., Lang D.J., et al. Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis. Schizophr Res 2012, 134(2-3):253-259.
101. Egan M.F., Kojima M., Callicott J.H., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112(2):257-269.
102. Dempster E., Toulopoulou T., McDonald C., et al. Association between BDNF val66 met genotype and episodic memory. Am J Med Genet B Neuropsychiatr Genet 2005, 134B(1):73-75.
103. Ho B.C., Milev P., O'Leary D.S., et al. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 2006, 63(7):731-740.
104. Goldberg T.E., Iudicello J., Russo C., et al. BDNF Val66Met polymorphism significantly affects d' in verbal recognition memory at short and long delays. Biol Psychol 2008, 77(1):20-24.
105. Mandelman S.D., Grigorenko E.L. BDNF Val66Met and cognition: all, none, or some? A meta-analysis of the genetic association. Genes Brain Behav 2012, 11(2):127-136.
106. Kraemer H.C., Kupfer D.J., Clarke D.E., et al. DSM-5: how reliable is reliable enough?. Am J Psychiatry 2012, 169(1):13-15.